Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of BEAM is 53 and suggests 105% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell